Printer Friendly

MACRONEX RECEIVES TWO NATIONAL INSTITUTES OF HEALTH GRANTS; MACROPHAGE TECHNOLOGY TO BE USED TO REGULATE AUTOIMMUNE AND INFLAMMATORY CONDITIONS

 RESEARCH TRIANGLE PARK, N.C., Dec. 31 /PRNewswire/ -- Macronex, Inc., today announced that it has received two Phase I Small Business Innovation Research (SBIR) grants. The grants are being funded by the National Institute of Allergy and Infectious Diseases of the National Institute of Health.
 Macronex's research is based on strategies which use macrophages as the therapeutic targets. Macrophages, as one of three key white blood cells, initiate, regulate and effect immune responses. Although commonly thought of as the scavengers of the immune system, macrophages have many other critical functions in the immune system, including the production and release of a wide variety of key signaling, messenger and effector molecules. They are found in all tissues and regulate many physiological events, including immune and inflammatory responses.
 According to Dr. George Cianciolo, Macronex's executive vice president for research and development, one grant will be used to conduct preclinical studies of a class of proprietary peptides and proteins that Macronex is developing as immunoregulating agents with potential applications in the treatment of inflammatory and autoimmune conditions, and graft rejection. The second grant will support Macronex's continuing investigation as potential human therapeutics of a class of unique, derivatized amino acids which have demonstrated immunosuppressive activities in murine models.
 "These funds will bolster our work on immune modulators," said Dennis Burns, president and chief executive officer. "We are excited about the potential for our macrophage technology in the treatment of many diseases, and pleased that others are also recognizing that potential and supporting our work."
 Macronex, a biopharmaceutical company, develops therapeutics for acute and chronic inflammatory and autoimmune diseases.
 -0- 12/31/92
 /CONTACT: Dr. George Cianciolo, executive vice president - research and development of Macronex, 919-481-4390; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for Macronex/


CO: Macronex, Inc. ST: North Carolina IN: MTC SU:

AH-GK -- NY005 -- 0855 12/31/92 10:20 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 31, 1992
Words:313
Previous Article:SHEFFIELD INDUSTRIES, INC. ANNOUNCES RECEIPT OF A TOTAL OF $2.416 MILLION OF INSURANCE PROCEEDS IN RESOLUTION OF PENDING CLAIMS
Next Article:CHAMBERS RECEIVES PERMIT FOR NEW OHIO LANDFILL
Topics:


Related Articles
IMMUNEX BEGINS SOLUBLE TNF RECEPTOR TRIALS; NIH LAUNCHES FIRST STUDY IN SEPSIS PATIENTS
MACRONEX APPOINTS NEW PRESIDENT AND CEO
MACRONEX ELECTS CEO OF CEPHALON TO BOARD OF DIRECTORS
Cytokine Networks and IDEC Pharmaceuticals Sign Licensing and Development Agreement
Signal Expands Patent Position In Key Map Kinase Gene Regulation Pathways with University of Massachusetts Licenses.
Cantab Licenses Therapeutic Applications of Anti-OX40 Antibodies.
BIOGEN/CURAGEN DEMONSTRATE ECM REGULATES GENE EXPRESSION.
AVANIR acquires MIF technology to treat autoimmune and inflammatory diseases.
HOLLIS-EDEN REPORTS HE2500 REDUCES PARALYSIS FROM EAE.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters